Publications by authors named "L Gladieff"
Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) at interval cytoreductive surgery for ovarian cancer improves overall survival but its role in recurrent disease is uncertain. We aimed to compare outcomes in patients treated with or without HIPEC during surgery for recurrent ovarian cancer.
Methods: The multicentre, open-label, randomised, phase 3 CHIPOR trial was conducted at 31 sites in France, Belgium, Spain, and Canada, and enrolled patients with first relapse of epithelial ovarian cancer at least 6 months after completing platinum-based chemotherapy.
Objective: Treatment of high-grade serous ovarian carcinomas relies on surgery and chemotherapy, potentially followed by bevacizumab and/or poly (ADP-ribose) polymerase inhibitors (PARPi). The modeled CA-125 ELIMination rate constant K (KELIM) is a pragmatic indicator of tumor primary chemosensitivity. Although it is well established that mutations are associated with platinum sensitivity, the relationship between status and KELIM score has yet to be elucidated.
View Article and Find Full Text PDFMismatch repair-deficient (dMMR) endometrial cancer (EC) is an inflamed phenotype with poor outcomes when meeting high-risk criteria and limited treatment options in the adjuvant setting. We report protocol-prespecified subgroup analysis of patients with dMMR tumors from the phase III ENGOT-en11/GOG-3053/KEYNOTE-B21 study (ClinicalTrials.gov identifier: NCT04634877) in newly diagnosed, high-risk EC after surgery with curative intent.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers aimed to determine the role of antibody-dependent cell-mediated cytotoxicity (ADCC) in avelumab's effectiveness and whether variations in the FcγR3A receptor can predict patient responses.
- * Findings confirmed the presence of FcγR3A+ natural killer (NK) cells in PD-L1-expressing GTN, and that avelumab enhances NK cell activity, further suggesting higher affinity FcγR3A variants may
Article Synopsis
- - Ovarian cancer is a major cause of death among gynecological cancers, and platinum-based chemotherapy is the primary treatment method, along with maintenance strategies to extend chemotherapy intervals.
- - Current maintenance treatments include bevacizumab and poly ADP-ribose polymerase inhibitors, but these can only be used once during the disease's progression, leaving a gap in treatment for patients experiencing relapses.
- - A new international Phase II trial is exploring a combination of a therapeutic cancer vaccine (OSE2101) and anti-PD1 (pembrolizumab) as a maintenance therapy for patients with platinum-sensitive recurrences, regardless of prior treatments.